Apellis Pharmaceuticals Inc. Common Stock (APLS)

FairStock Score: 12/100 — RISKY

Key Financials

Concerns

• Trades significantly above Graham Number ($3) with negative 1089% margin of safety—limited downside protection
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 5.9% year-over-year signals potential demand weakness or market share loss
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Apellis Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $5.2 billion. Revenue stands at $1.0 billion, though the company is currently unprofitable. From a quality standpoint, Apellis shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 1.3 warrants caution. On valuation, the stock is commanding a steep 227.4x multiple, with trades far above its Graham Number ($3) with no margin of safety. Growth dynamics show revenue growing at -5.9% and profit growth of -62.2%. Our composite FairStock Score of 12/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

At 227x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer